Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Good afternoon, everyone, and thank you for joining us today. I am Dr. Meesha Dogan, CEO, Co-Founder and Director of Cardio Diagnostics. We truly appreciate your support of the company and the opportunity to share where we are, meaningful milestones we've accomplished and how we are leading the next frontier in precision cardiovascular medicine. We are at a pivotal moment in cardiovascular medicine. Despite decades of innovation, heart disease remains the leading cause of death worldwide. At the same time, advances in molecular biology and artificial intelligence are opening entirely new possibilities for how we assess, detect and manage disease. At Cardio Diagnostics, we've spent more than a decade building at the intersection of those 2 forces, precision molecular biology and AI. What started as a scientific vision has evolved into commercially available tests, a growing evidence base, reimbursement progress and expanding partnerships both domestically and internationally. Joining me today is Dr. Warren Hosseinion, Chairman of Cardio Diagnostics. We are excited to share how we are helping move cardiovascular care from reactive to more proactive and personalized and how we're positioning the company for long-term growth. We're energized by the opportunity ahead, and we appreciate you being part of the conversation. Before we begin, just a quick note. Today's presentation includes forward-looking statements that involve risks and uncertainties. We encourage you to review our SEC filings for more detail. With that, I will hand it off to Dr. Hosseinion for his remarks.

Thank you, Meesha. Good afternoon, everyone. Thank you for joining us today, and thank you for your continued